Item 5.07 Submission of Matters to a Vote of Security Holders.

On December 7, 2022, Xenetic Biosciences, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast their votes as described below. The Annual Meeting was partially adjourned to December 21, 2022 solely with respect to the voting on Proposal Four. The Annual Meeting will resume solely with respect to Proposal Four at 10:00 a.m. Eastern Time on December 21, 2022 and will continue to be held virtually via live audio-only webcast at www.virtualshareholdermeeting.com/XBIO2022. Below is a summary of the proposals and corresponding votes.

1. The Company's stockholders approved the election of the following seven


    nominees with each director receiving votes as follows:




Name                         For      Withheld    Broker Non-Votes
Dr. Grigory Borisenko     4,262,295     734,810      2,866,140
Dr. James Callaway        3,615,669   1,381,436      2,866,140
Mr. Firdaus Jal Dastoor   4,245,854     751,251      2,866,140
Mr. Jeffrey Eisenberg     4,271,238     725,867      2,866,140
Dr. Roger Kornberg        3,607,135   1,389,970      2,866,140
Mr. Adam Logal            4,253,923     743,182      2,866,140
Mr. Alexey Vinogradov     4,273,562     723,543      2,866,140

2. The Company's stockholders voted upon and approved the ratification of the


    selection of Marcum LLP as the independent registered public accounting firm
    of the Company for its fiscal year ending December 31, 2022. The votes on this
    proposal were as follows:




   For      Against   Abstained   Broker Non-Votes
7,370,441   434,234    58,570            -




  3. The Company's stockholders voted upon and approved, on a non-binding,
     advisory basis, the Company's named executive officer compensation. The votes
     on this proposal were as follows:




   For      Against   Abstained   Broker Non-Votes
4,231,759   699,669    65,677        2,866,140

4. Proposal Four was to approve an amendment to the Company's Articles of

Incorporation to increase the authorized number of shares of the Company's

common stock from 50,000,000 shares to 100,000,000 shares. The Company has

adjourned the Annual Meeting solely with respect to Proposal Four to provide

its stockholders additional time to vote on such proposal. Support for

Proposal Four has exceeded 80% of the votes cast on the proposal. However, the

affirmative vote of holders of more than 50% of all of the Company's issued

and outstanding shares of common stock is necessary for Proposal Four to be


    approved.

No other matters were considered or voted upon at the Annual Meeting.

















  2

© Edgar Online, source Glimpses